Fulcrum Therapeutics, Inc. reported a significant net loss of $74.9 million for the fiscal year ending December 31, 2025, compared to a loss of $9.7 million in the previous year. The company's accumulated deficit has now reached $594.3 million. The decline in financial performance is attributed primarily to the termination of a collaboration agreement with Sanofi, which had previously generated $80 million in revenue in 2024. Operating expenses decreased to $84.8 million from $101.9 million in 2024, driven by reduced research and development costs, particularly related to the suspension of the losmapimod program.
Fulcrum's lead product candidate, pociredir, is currently in clinical development for sickle cell disease (SCD). The company has completed dosing in the Phase 1b PIONEER trial, with promising results indicating a mean absolute increase in fetal hemoglobin (HbF) of 12.2% after 12 weeks of treatment. The trial also showed improvements in markers of hemolysis and anemia. Following the completion of this trial, Fulcrum is activating sites for an open-label extension trial and plans to initiate a registration-enabling trial in the second half of 2026, pending feedback from the FDA.
As of December 31, 2025, Fulcrum had cash, cash equivalents, and marketable securities totaling approximately $352.3 million, which the company believes will fund its operations into 2029. The company has entered into an at-the-market offering program to raise additional capital, with the potential to offer up to $100 million in common stock. However, the company acknowledges the need for substantial additional funding to support ongoing clinical development and operational costs, particularly as it continues to advance pociredir and explore new product candidates.
Fulcrum's workforce has been reduced to 55 full-time employees, including 19 with advanced degrees, as part of its strategy to manage costs while focusing on its core programs. The company emphasizes the importance of attracting and retaining talent to support its mission of developing therapies for genetically defined rare diseases. Despite the challenges, Fulcrum remains committed to its research and development efforts, particularly in the area of hematology, and is exploring additional collaborations to enhance its product pipeline.
About Fulcrum Therapeutics, Inc.
Fulcrum Therapeutics is a biopharmaceutical company focused on developing small molecules to treat genetically defined rare diseases, particularly hematologic conditions like sickle cell disease. Its pipeline includes product candidates aimed at increasing fetal hemoglobin levels and addressing underlying genetic causes. The company leverages proprietary discovery platforms, collaborates with industry partners, and relies on contract manufacturing, targeting high unmet medical needs with a focus on innovation and targeted therapies.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.